Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.
about
Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentPharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaBiomarkers for determining the prognosis in chronic myelogenous leukemiaResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsMATE1 regulates cellular uptake and sensitivity to imatinib in CML patientsIncreased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drugNCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaAntibody-based therapeutics to watch in 2011.OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib.Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase.Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agentAssociation between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.Interferon gamma modulates sensitivity of CML cells to tyrosine kinase inhibitors.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reactionHigh imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patientsTIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsInsights into the stem cells of chronic myeloid leukemia.SLC22 transporter family proteins as targets for cytostatic uptake into tumor cells.Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.Navigating the road toward optimal initial therapy for chronic myeloid leukemia.Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia.Mechanisms of resistance to BCR-ABL kinase inhibitors.Predicting the response of CML patients to tyrosine kinase inhibitor therapy.Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase.Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients.Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.Selection of therapy: rational decisions based on molecular events.Evolution of therapies for chronic myelogenous leukemia.Molecular resistance: an early indicator for treatment change?Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and Monitoring.Management options for refractory chronic myeloid leukemia: considerations for the elderly.The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib.Ever-advancing chronic myeloid leukemia treatment.
P2860
Q26766299-D54E4DBD-2F20-4983-85EF-66B560A14819Q26781539-46AF1B5D-021B-4D1A-B673-E23AC4D43925Q26824660-DEAFE48B-770C-49BC-B5C8-ACC67530B793Q27028181-B5FCFA52-3324-4A28-A98D-209C9815D6D3Q30313870-53B85C64-9A69-4C2F-A48A-647354BB9952Q33815980-EC04ACF6-70AC-4FCE-B4D2-A76F75531065Q33878636-0BA707A4-959B-43C9-A3C6-0BF4039C47F3Q34065271-0649446F-C19A-49F9-B525-811E01BF2A1AQ34522789-8C70FA08-FE88-4F2A-8E95-F1C114BE08D4Q34570079-B4170FCB-52D2-45F8-AD24-99E0F2DD6D2EQ34774289-75C6EC0E-AFD6-4D76-B1CB-3B7B1E12E475Q35708124-AED21C09-8E3A-48C7-846A-CB73C9198537Q35930616-516DFC99-2C83-41B2-9094-C040807B176AQ36006408-64B97ED0-0186-4866-A08F-1C8D34305128Q36184500-B6500CC6-A852-4C72-B7A0-41DDA383160FQ36483712-7A5EB63D-C592-44C0-B66B-EC8D8A3BA3E6Q36579071-2F49A70E-21E5-43D8-A020-2FA8FBF0CA5EQ36597361-06938673-EA92-482A-94DF-F4D24F3BCAD0Q37026032-D81B31FE-B160-412D-A8D7-F61454088A88Q37144877-3D26B766-47DD-4A11-B89E-EBD555F8207FQ37381574-CE506DA2-D366-4F31-8351-51CEED21F24FQ37509428-4B5B0F32-8631-404C-99B6-D008CC896B0FQ37791423-48493890-4ACE-4D6D-9945-051CD7E7C4B5Q37824862-20BEECCD-80C5-40F2-A220-01F94398940FQ37827278-D24528D6-E63F-4D70-8308-AD6DB8572C7CQ37831034-5620F0C8-08D4-4588-9D99-BF826B2403E8Q37836922-C405D890-4FA1-4604-A1FF-2E98F9D5E4E9Q37836923-28078727-8EE7-4DAB-B054-817DCD2CF79AQ37859303-193A3D73-4C02-419C-B2B8-6F0779B5C87CQ37862942-86CDEE6E-F4F1-4000-81E9-BB82B9AC53B4Q37888714-5ED4CC43-1750-4AC0-B976-225A2573473AQ37918304-623E16A9-FF18-4E98-A15D-97274CB59F4EQ37952910-E1D54014-1391-447E-BD12-63E32D0820BBQ37966915-2DF22364-0267-4DB0-8E49-7E466D7DD8F2Q37979587-BCBB51E5-E2A5-4FFA-ADC9-974381BDFBB1Q38095956-F57A42C4-3654-46CE-BCC0-597958837C36Q38101471-A4580337-F670-4103-9F14-770A852B745FQ38113416-A295A529-7E95-4097-8CA8-29E5A7C066EDQ38150978-8D8F0E1C-81F9-48C7-BC25-6D710C4A6445Q38164565-7F418D00-EE28-46D2-997A-DD732DD8A77D
P2860
Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Functional activity of the OCT ...... eukemia treated with imatinib.
@en
Functional activity of the OCT ...... eukemia treated with imatinib.
@nl
type
label
Functional activity of the OCT ...... eukemia treated with imatinib.
@en
Functional activity of the OCT ...... eukemia treated with imatinib.
@nl
prefLabel
Functional activity of the OCT ...... eukemia treated with imatinib.
@en
Functional activity of the OCT ...... eukemia treated with imatinib.
@nl
P2093
P921
P356
P1476
Functional activity of the OCT ...... eukemia treated with imatinib.
@en
P2093
Amity Frede
Jane Engler
Michael Osborn
Paul W Manley
Phuong Dang
Stephanie Zrim
Timothy P Hughes
Verity A Saunders
P304
P356
10.1200/JCO.2009.26.5819
P407
P577
2010-04-26T00:00:00Z